期刊文献+

抗人ICAM-1单链抗体表达载体的构建及在大肠杆菌中的表达 被引量:2

Construction of Expression Vector for Anti-Human Intercellular Adhesion Molecule-1 Single Chain Fragment Variable and Its Expression in E.coli
下载PDF
导出
摘要 目的构建抗人细胞间黏附分子-1(ICAM-1)单链抗体(ScFv)的表达载体,并在大肠肝菌中表达。方法从分泌ICAM-1单抗的杂交瘤细胞中提取RNA,用RT-PCR扩增抗体VH和VL基因,重叠延伸PCR扩增人ICAM-1-ScFv基因,将其连接到pET-22b(+)载体上,转化大肠杆菌BL2(DE3),IPTG诱导表达,表达产物纯化及复性后,检测特异性及活性。结果序列分析表明抗ICAM-1 ScFv基因全长为744bp,编码247个氨基酸,其中含357bp的VH基因片段和342bp的VL基因片段。表达蛋白以包涵体形式存在,表达量占菌体总蛋白的32%。经变性和复性后,纯度达80%以上,复性率达25%。Western blot和ELISA检测,ScFv均可与ICAM-1抗原特异性结合。细胞黏附试验表明ScFv能抑制ICAM-1与HSB2细胞间的黏附,其作用稍弱于亲本mAb。结论已成功构建了抗人ICAM-1的ScFv表达载体,其表达产物具有抗体特异性和活性。 Objective To construct the expression vector for anti-human intercellular adhesion molecule-1 (ICAM-1) single chain fragment variable (ScFv) and express in E. coli .Methods Extract RNA from the hybridoma cells secreting McAb against ICAM-1 for amplifi- cation of VH and VL genes by RT-PCR. Amplify human ICAM-1 ScFv gene by SOE-PCR and insert into vector pET-22b( + ). Transform the constructed recombinant plasmid to E. coil for expression under induction of IFIG. The expressed product were purified,re-naturalized and de- termined for specificity and activity. Results Sequencing result showed that the amplified ICAM-1 ScFv gene fragment, at a full-length of 744 bp, encoded 247 amino acids and consisted of Vii and VL genes,at lengths of 357 bp and 342 bp respectively,and a 45 bp tlexible linker. The expressed product,in a form of inclusion body,contained 32% of total somatic protein and reached a purity of more than 80% after denatu- ration and renaturation. The refolding rate was 25%. Both Western blot and ELISA showed specific binding of ScFv to ICAM-1 antigen. Cell ad- hesion test proved that the ScFv inhibited the adhesion of ICAM-1 to HSB2 cells. However, compared with that of its parental McAb, the in- hibitory effect of ScFv was slightly weak. Conclusion The expression vector for anti-human ICAM-1 ScFv was successfully constructed, and the expressed product showed antibody specificity and activity.
出处 《中国生物制品学杂志》 CAS CSCD 2008年第5期405-409,共5页 Chinese Journal of Biologicals
基金 吉林省科技发展计划重点项目(20060929) 军事医学科学院创新基金
关键词 细胞间黏附分子-1 单链抗体 表达 活性 Intercellular adhesion molecule- 1 (ICAM- 1 ) Single chain fragment variable (ScFv) Expression Activity
  • 相关文献

参考文献8

  • 1Colcher D,Bird R,Roselli M,et al.In vivo tumor targeting of a recombinant single-chain antigen-binding protein.J Nat1 Cancer Inst,1990,82(14):1191-1197.
  • 2Yokota T,Milenic DE,Whitlow M,et al.Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.Cancer Res,1992,52(12):3402-3408.
  • 3Lamers CH,Sleijfer S,Willemsen RA,et al.Adoptive immuno-gene therapy of cancer with single chain antibody[scFv (Ig)] gene modified T lymphocytes.J Biol Regul Homeost Agents,2004,18(2):134-140.
  • 4孙红,万忠海,张国利,吴广谋,朱平,岳玉环.抗ICAM-1单克隆抗体的制备及其活性[J].中国生物制品学杂志,2008,21(4):308-311. 被引量:3
  • 5Cu ZY,Weidenhaupt M,Ivanova N,et al.Chromatographic methods for the isolation of,and refolding of proteins form,Escherichia coli inclusion bodies.Protein Expr Purif,2002,25(1):174-179.
  • 6Sinacola JR,Robinson AS.Rapid refolding and polishing of single-chain antibodies from Escherichia coli inclusion bodies.Protein Expr Purif,2002,26(2):301-308.
  • 7Lu HQ,Zang YH,Ze YG,et al.Expression,refolding,and characterization of a novel recombinant dual human stem cell factor.Protein Expr Purif,2005,43(2):126-132.
  • 8Choi GH,Lee DH,Min WK,et al.Cloning,expression,and characterization of single-chain variable fragment antibody against mycotoxin deoxynivalenol in recombinant Escherichia coli,Protein Expr Purif,2004,35(1):84-92.

二级参考文献9

  • 1赵宏霞,夏咸柱,鲁继荣,岳玉环,杨松涛,朱平.ICAM-1及其受体在高致病性禽流感病毒性肺炎中的作用研究[J].中国病毒学,2006,21(1):38-42. 被引量:6
  • 2Simmons D, Makgoba MW,Secd B.ICAM,an adhesion ligand of LFA-1, is homologous to the neural cell adhesion molecule NCAM. Nature, 1988, 331 (6157) :624-627.
  • 3Hayashi T, Hasegawa K, Ichinohe N. ICAM-1 expression on endothelium and systemic cytokine production in cutaneous neutrophilic leukocytoclastic vasculitis in NZBXNZWF1 mice 52.
  • 4Hallahan DE, Geng L, Shyr Y. Effects of intercellular adhesion molecule- 1 (ICAM-1) null mutation on radiation-induced pulmonary fibrosis and respiratory insufficiency in mice.J Natl Cancer Inst,2002,94(10) :733- 741.
  • 5Kohler G, Milstein C. Continuous euhures of fused ceils secreting antibody of predefined specificity. Nature, 1975,256(5517) :495-497.
  • 6沈关心,周汝麟.现代免疫学实验技术.第2版,武汉:湖北科学技术出版社,2001.32-37.
  • 7Mileski MJ, Burkhart D, Hunt JL, et al. Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (Enlimomab) in the treatment of partial-thickness burn injury, J Trauma,2003,54(5) :950-958.
  • 8Argenbright LW, Letts LG, Rothleln R. Monoclonal antibodies to the leukocyte membrane CD18 glyeoprotein complex and to intercellular adhesion molecule-1 inhibit leukocyte-endothelial adhesion in rabbits. J Leukoc Biol, 1991,49(3) :253-257.
  • 9Yoshida N, Smith E, Faull RJ, et al. Anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. Am J Physiol, 1992,262 (6) : H1891-H1898.

共引文献2

同被引文献30

  • 1马颖,邹全明.单链抗体及其在生物医学中的应用[J].免疫学杂志,2006,22(z1):1-5. 被引量:16
  • 2赵岩,王清明,付学奇,陈吉中,范国才,陈惠鹏.噬菌体抗体库的构建及抗乳腺癌细胞单链抗体的筛选[J].生物工程学报,2004,20(5):667-672. 被引量:6
  • 3张智清,姚立红,侯云德.含P_RP_L启动子的原核高效表达载体的组建及其应用[J].病毒学报,1990,6(2):111-116. 被引量:178
  • 4何维.细胞因子.巴德年,主编.当代免疫学技术与应用[M].北京:北京医科大学,中国协和医科大学联合出版社,一版,1998,52.
  • 5Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tu- mour necrosis factor and interleukin 6 take the stage [J]. Ann Rheum Dis, 2011, 70 (Suppl 1): i104-i108.
  • 6Silva LC, Ortigosa LC, Benard G. Anti-TNF-α agents in the treat- ment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls [J]. Immunotherapy, 2010, 2 (6): 817-833.
  • 7Simsek I. TNF inhibitors-new and old agents for rheumatoid arthri- tis [J]. Bull NYU Hosp Jt Dis, 2010, 68 (3): 204-210.
  • 8Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated dis- eases: an update upon efficacy and adverse events [J]. Int J Im- munopathol Pharmacol, 2009, 22 (3): 557-565.
  • 9Rigopoulos D, Korfitis C, Gregoriou S, et al. Infliximab in derma-tological treatment: beyond psoriasis [J~. Expert Opin Biol Ther, 2008, 8 (1): 123-133.
  • 10Shealy D J, Visvanathan S. Anti-TNF antibodies: lessons from the past, roadmap for the future [J]. Handb Exp Pharmacol, 2008, (181): 101-129.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部